{"id":55994,"date":"2023-04-19T13:07:47","date_gmt":"2023-04-19T11:07:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/caredx-showcases-leadership-with-over-55-oral-presentations-and-posters-at-the-43rd-annual-meeting-scientific-sessions-of-the-international-society-for-heart-and-lung-transplantation\/"},"modified":"2023-04-19T13:07:47","modified_gmt":"2023-04-19T11:07:47","slug":"caredx-showcases-leadership-with-over-55-oral-presentations-and-posters-at-the-43rd-annual-meeting-scientific-sessions-of-the-international-society-for-heart-and-lung-transplantation","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/caredx-showcases-leadership-with-over-55-oral-presentations-and-posters-at-the-43rd-annual-meeting-scientific-sessions-of-the-international-society-for-heart-and-lung-transplantation\/","title":{"rendered":"CareDx Showcases Leadership with Over 55 Oral Presentations and Posters at the 43rd Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation"},"content":{"rendered":"
\n

\nData Highlights the Value of HeartCare and AlloSure Lung in Clinical Practice<\/i><\/p>\n

\nLeading Experts Present Latest Advancements in Heart and Lung Transplantation During CareDx Symposia<\/i><\/p>\n

BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers \u2013 today announced a leading presence at the 43rd<\/sup> annual meeting & scientific sessions of the International Society for Heart and Lung Transplantation (ISHLT) with over 55 oral presentations and posters, and two symposia covering the latest advancements in surveillance and the clinical utility of these advancements in real-world applications for both heart and lung transplantation. The event will be held April 19-22 in Denver, Colorado.<\/p>\n

\n\u201cWe are exceedingly proud to have a remarkable presence at this year\u2019s ISHLT meeting with HeartCare data showing significant clinical benefits and compelling data supporting the advancement of AlloSure Lung into clinical practice,\u201d said Reg Seeto, CEO and President of CareDx. \u201cThe significant body of evidence presented at ISHLT demonstrates the value of routinely incorporating CareDx\u2019s non-invasive molecular solutions in heart and lung transplant clinical decision making.\u201d<\/p>\n

<\/a><\/p>\n

\n\u201cHeartCare is a comprehensive molecular tool that we believe when used for surveillance provides insight into the risk of future significant clinical events compared to biopsies alone. Integrating this additional information will hopefully allow clinicians to further optimize and individualize post-transplant medical therapy,\u201d said Dr. Jeffrey Teuteberg, MD, Cardiologist, and Professor of Cardiovascular Medicine at Stanford. \u201cIn fact, at Stanford Health Care we have moved away from routine surveillance with biopsies to multimodality molecular surveillance starting at one month as the standard for all patients who receive a cardiac transplant. In doing so, we have maintained excellent short and long-term outcomes and patients rarely require a biopsy.\u201d<\/p>\n

\nCareDx has assembled leading experts in the field who will review the use of HeartCare\u2122 and AlloSure\u00ae Lung on clinical decision-making and in the management of challenging real-world scenarios.<\/p>\n